Teva Pharmaceuticals (TEVA) Stock Declines Today on Generic Copaxone Approval

NEW YORK (TheStreet) -- Teva Pharmaceuticals shares are down 2.57% to $63.24 in trading on Monday continuing the decline the drug maker's Tel Aviv shares experienced in trading on Sunday after the FDA approved a generic version of its top-selling multiple sclerosis drug, Copaxone.Copaxone accounts for about half of Teva's profits and investors are worried that the approval 20 mg generic drug Glatopa, which was developed by a unit of Novartis AG , could hurt its bottom line.The news of stif...